Reorganisation key for Piramal Enterprise
The mention of Piramal could bring back memories of its deal with Abbott India, when Piramal Healthcare sold its formulation business for about Rs 17,000 crore. A lot has changed since and the Street’s interest in Piramal Enterprise’s stock, too, gradually receded. For instance, Sarabjit Kour Nangra, vice-president of Research, Angel Broking, who had an active coverage on Piramal Healthcare says after the sale, the residual businesses were only cash and contract research and manufacturing. So, not many analysts tracked it. However,.....